Reported Saturday, Tenaya Therapeutics Reports TN-201 Well Tolerated At 3E13 And 6E13 vg/kg With Managed Immunogenicity And No Dose-Limiting Toxicities In MyPEAK-1
Benzinga Newsdesk 11 months ago
News
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular ResearchTN-201 Has Been Generally Well Tolerated at Both DosesLonger-term Follow Up of
- MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research
- TN-201 Has Been Generally Well Tolerated at Both Doses
- Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy
- Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression